Market Currents
Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel...
-
Thursday, December 8, 2011, 11:33 AM ETAffymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
